| scholarly article | Q13442814 |
| P50 | author | Massimiliano Mazzone | Q38327282 |
| Luigi Naldini | Q16574299 | ||
| Paolo M. Comoglio | Q37381902 | ||
| P2093 | author name string | Paolo Michieli | |
| Antonino Sottile | |||
| Cristina Basilico | |||
| Silvia Cavassa | |||
| P433 | issue | 1 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 61-73 | |
| P577 | publication date | 2004-07-01 | |
| P1433 | published in | Cancer Cell | Q280018 |
| P1476 | title | Targeting the tumor and its microenvironment by a dual-function decoy Met receptor | |
| P478 | volume | 6 |
| Q38956369 | A DNA aptamer to c-Met inhibits cancer cell migration. |
| Q36777999 | A high affinity hepatocyte growth factor-binding site in the immunoglobulin-like region of Met |
| Q38773268 | A novel antagonist anti-cMet antibody with antitumor activities targeting both ligand-dependent and ligand-independent c-Met receptors |
| Q38304282 | A novel tyrosine kinase switch is a mechanism of imatinib resistance in gastrointestinal stromal tumors |
| Q34800852 | A role for septins in the interaction between the Listeria monocytogenes INVASION PROTEIN InlB and the Met receptor |
| Q38965918 | ADAM10 correlates with uveal melanoma metastasis and promotes in vitro invasion |
| Q24546366 | Ab-induced ectodomain shedding mediates hepatocyte growth factor receptor down-regulation and hampers biological activity |
| Q33942266 | Activation of HER family members in gastric carcinoma cells mediates resistance to MET inhibition. |
| Q35551938 | Adenovirus expressing dual c-Met-specific shRNA exhibits potent antitumor effect through autophagic cell death accompanied by senescence-like phenotypes in glioblastoma cells |
| Q38878552 | An intramolecular G-quadruplex structure formed in the human MET promoter region and its biological relevance |
| Q30428363 | An orally bioavailable c-Met kinase inhibitor potently inhibits brain tumor malignancy and growth |
| Q24561588 | An uncleavable form of pro-scatter factor suppresses tumor growth and dissemination in mice |
| Q37138521 | Anti-c-Met antibodies recognising a temperature sensitive epitope, inhibit cell growth |
| Q39750624 | Beta4 integrin activates a Shp2-Src signaling pathway that sustains HGF-induced anchorage-independent growth |
| Q35571904 | Breast cancer stem cells, cytokine networks, and the tumor microenvironment |
| Q37750050 | C-MET as a new therapeutic target for the development of novel anticancer drugs |
| Q39472261 | Cabozantinib (XL184), a Novel MET and VEGFR2 Inhibitor, Simultaneously Suppresses Metastasis, Angiogenesis, and Tumor Growth |
| Q94367553 | Cabozantinib Loaded DSPE-PEG2000 Micelles as Delivery System: Formulation, Characterization and Cytotoxicity Evaluation |
| Q39162597 | Cell Surface Receptor Targeted Biomimetic Apatite Nanocrystals for Cancer Therapy |
| Q39684133 | Cell delivery of Met docking site peptides inhibit angiogenesis and vascular tumor growth. |
| Q37575602 | Changing the clinical picture of challenging tumors: tales becoming reality? |
| Q34978329 | Combination strategy targeting VEGF and HGF/c-met in human renal cell carcinoma models |
| Q36407762 | Cross talk between c-Met and epidermal growth factor receptor during retinal pigment epithelial wound healing |
| Q90702159 | Current advances of targeting HGF/c-Met pathway in gastric cancer |
| Q41901776 | Dasatinib Modulates Invasive and Migratory Properties of Canine Osteosarcoma and has Therapeutic Potential in Affected Dogs |
| Q38201707 | Development of systemic therapy for hepatocellular carcinoma at 2013: updates and insights. |
| Q34782774 | Drug development of MET inhibitors: targeting oncogene addiction and expedience |
| Q42282846 | Dual Constant Domain-Fab: A novel strategy to improve half-life and potency of a Met therapeutic antibody. |
| Q53232399 | Dysregulation of HGF/c-Met signal pathway and their targeting drugs in lung cancer |
| Q34616966 | Epigallocatechin-3-gallate inhibits paracrine and autocrine hepatocyte growth factor/scatter factor-induced tumor cell migration and invasion |
| Q36318551 | Exploring the tumour environment: cancer-associated fibroblasts as targets in cancer therapy |
| Q33688558 | Expression of MET in circulating tumor cells correlates with expression in tumor tissue from advanced-stage lung cancer patients |
| Q36489766 | Extracellular angiogenic growth factor interactions: an angiogenesis interactome survey |
| Q35548351 | Fatty acid carbon is essential for dNTP synthesis in endothelial cells |
| Q36983715 | Fibroblasts as novel therapeutic targets in chronic inflammation |
| Q30581656 | Four individually druggable MET hotspots mediate HGF-driven tumor progression. |
| Q46722755 | Genomic amplification of MET with boundaries within fragile site FRA7G and upregulation of MET pathways in esophageal adenocarcinoma |
| Q38883827 | HGF/Met Signaling in Head and Neck Cancer: Impact on the Tumor Microenvironment. |
| Q51152435 | HGF/c-MET Axis in Tumor Microenvironment and Metastasis Formation. |
| Q41893732 | Hepatocyte growth factor and sonic Hedgehog expression in cerebellar neural progenitor cells costimulate medulloblastoma initiation and growth |
| Q92715639 | High-Affinity Human Anti-c-Met IgG Conjugated to Oxaliplatin as Targeted Chemotherapy for Hepatocellular Carcinoma |
| Q89231936 | Identification of genomic and molecular traits that present therapeutic vulnerability to HGF-targeted therapy in glioblastoma |
| Q37403891 | In Vitro and In Vivo Activity of Cabozantinib (XL184), an Inhibitor of RET, MET, and VEGFR2, in a Model of Medullary Thyroid Cancer |
| Q40203442 | Inhibition of c-Met as a therapeutic strategy for esophageal adenocarcinoma |
| Q38859217 | Inhibition of ligand-independent constitutive activation of the Met oncogenic receptor by the engineered chemically-modified antibody DN30. |
| Q34398276 | Inhibition of the MET Receptor Tyrosine Kinase as a Novel Therapeutic Strategy in Medulloblastoma |
| Q30437740 | Interactions between PTEN and receptor tyrosine kinase pathways and their implications for glioma therapy |
| Q28253680 | Invasive growth: a MET-driven genetic programme for cancer and stem cells |
| Q88613156 | Isoquercitrin, ingredients in Tetrastigma hemsleyanum Diels et Gilg, inhibits hepatocyte growth factor/scatter factor-induced tumor cell migration and invasion |
| Q52318134 | Known and novel roles of the MET oncogene in cancer: a coherent approach to targeted therapy. |
| Q62559525 | Leukocyte cell-derived chemotaxin 2 antagonizes MET receptor activation to suppress hepatocellular carcinoma vascular invasion by protein tyrosine phosphatase 1B recruitment |
| Q36660673 | MET As a Possible Target for Non–Small-Cell Lung Cancer |
| Q37232416 | MET as a target for treatment of chest tumors |
| Q38389999 | MET genetic lesions in non-small-cell lung cancer: pharmacological and clinical implications |
| Q37458626 | MET inhibition overcomes radiation resistance of glioblastoma stem-like cells |
| Q28272688 | MET molecular mechanisms and therapies in lung cancer |
| Q39643704 | MET mutations in cancers of unknown primary origin (CUPs). |
| Q37811895 | MET signalling: principles and functions in development, organ regeneration and cancer |
| Q89603062 | MET targeting: time for a rematch |
| Q60909538 | MET/HGF Co-Targeting in Pancreatic Cancer: A Tool to Provide Insight into the Tumor/Stroma Crosstalk |
| Q27008925 | MET: A Critical Player in Tumorigenesis and Therapeutic Target |
| Q54586755 | MET: new target, new combinations |
| Q39121333 | MET: roles in epithelial-mesenchymal transition and cancer stemness |
| Q37995523 | Management of hepatocellular carcinoma: beyond sorafenib. |
| Q38669280 | Mechanisms of Resistance to EGFR Tyrosine Kinase Inhibitors and Therapeutic Approaches: An Update |
| Q42505884 | Met signaling regulates growth, repopulating potential and basal cell-fate commitment of mammary luminal progenitors: implications for basal-like breast cancer. |
| Q39978074 | Metron factor-1 prevents liver injury without promoting tumor growth and metastasis |
| Q84806879 | Mimics of the Dimerization Domain of Hepatocyte Growth Factor Exhibit Anti-Met and Anticancer Activity |
| Q46362794 | Model of vascular desmoplastic multispecies tumor growth |
| Q51091805 | Molecular Pathways: Receptor Ectodomain Shedding in Treatment, Resistance, and Monitoring of Cancer |
| Q53789447 | Monoclonal Antibodies against the MET/HGF Receptor and Its Ligand: Multitask Tools with Applications from Basic Research to Therapy |
| Q34285473 | Monovalency unleashes the full therapeutic potential of the DN-30 anti-Met antibody |
| Q39415245 | Multifaceted Interpretation of Colon Cancer Stem Cells. |
| Q36346969 | Necrosis- and apoptosis-related Met cleavages have divergent functional consequences |
| Q46835399 | Neoadjuvant selective COX-2 inhibition down-regulates important oncogenic pathways in patients with esophageal adenocarcinoma |
| Q36488744 | New signals from the invasive front |
| Q37883394 | Paradoxical action of growth factors: antiproliferative and proapoptotic signaling by HGF/c-MET. |
| Q34273411 | Phage displayed peptides/antibodies recognizing growth factors and their tyrosine kinase receptors as tools for anti-cancer therapeutics |
| Q33285431 | Plexin-B1 plays a redundant role during mouse development and in tumour angiogenesis |
| Q33652455 | Potential therapeutics specific to c-MET/RON receptor tyrosine kinases for molecular targeting in cancer therapy |
| Q38782345 | Preclinical and clinical evaluation of MET functions in cancer cells and in the tumor stroma. |
| Q37143367 | Prevention of hypoxia by myoglobin expression in human tumor cells promotes differentiation and inhibits metastasis |
| Q38007133 | Progress in cancer therapy targeting c-Met signaling pathway |
| Q37472880 | Proteolytic cleavages give receptor tyrosine kinases the gift of ubiquity. |
| Q64077603 | Proteolytic cleavages of MET: the divide-and-conquer strategy of a receptor tyrosine kinase |
| Q37380418 | Reduced Proteolytic Shedding of Receptor Tyrosine Kinases Is a Post-Translational Mechanism of Kinase Inhibitor Resistance |
| Q46920527 | Rho/ROCK-dependent pseudopodial protrusion and cellular blebbing are regulated by p38 MAPK in tumour cells exhibiting autocrine c-Met activation |
| Q47977359 | Role of glutamine and interlinked asparagine metabolism in vessel formation |
| Q24683896 | Scatter factor/hepatocyte growth factor in brain tumor growth and angiogenesis |
| Q37730020 | Selection criteria for c-Met-targeted therapies: emerging evidence for biomarkers |
| Q58164852 | Silencing the MET oncogene leads to regression of experimental tumors and metastases |
| Q33816457 | Single chain anti-c-Met antibody conjugated nanoparticles for in vivo tumor-targeted imaging and drug delivery |
| Q34753763 | Single-molecule photobleaching reveals increased MET receptor dimerization upon ligand binding in intact cells |
| Q44643220 | Soluble c-Met in serum of patients with multiple myeloma: correlation with clinical parameters |
| Q44601949 | Soluble c-Met protein as a susceptible biomarker for gastric cancer risk: A nested case-control study within the Korean Multicenter Cancer Cohort |
| Q58726253 | Status of Agents Targeting the HGF/c-Met Axis in Lung Cancer |
| Q29618873 | Stromal fibroblasts in cancer initiation and progression |
| Q24307789 | Structural characterization of autoinhibited c-Met kinase produced by coexpression in bacteria with phosphatase |
| Q35967197 | Suppression of Tumor Invasion and Metastasis by Concurrent Inhibition of c-Met and VEGF Signaling in Pancreatic Neuroendocrine Tumors |
| Q59129187 | Synthesis of novel 6,7-dimethoxy-4-anilinoquinolines as potent c-Met inhibitors |
| Q39098665 | Targeted therapy by gene transfer of a monovalent antibody fragment against the Met oncogenic receptor. |
| Q37533648 | Targeted therapy for malignant glioma patients: lessons learned and the road ahead |
| Q38856729 | Targeting c-MET in gastrointestinal tumours: rationale, opportunities and challenges |
| Q64119664 | Targeting stem cells in the realm of drug-resistant breast cancer |
| Q36766188 | Targeting the HGF-cMET Axis in Hepatocellular Carcinoma |
| Q37013777 | Targeting the HGF/Met signaling pathway in cancer therapy |
| Q36142604 | Targeting the HGF/Met signalling pathway in cancer. |
| Q24606259 | Targeting the Hepatocyte Growth Factor–cMET Axis in Cancer Therapy |
| Q37792116 | Targeting the MET oncogene in cancer and metastases. |
| Q38002473 | Targeting the Met pathway in lung cancer |
| Q37331862 | Targeting the Met signaling pathway in renal cancer. |
| Q27011423 | Targeting the epithelial to mesenchymal transition in glioblastoma: the emerging role of MET signaling |
| Q38216590 | Targeting the oncogenic Met receptor by antibodies and gene therapy |
| Q36472008 | Targeting the stromal microenvironment in chronic inflammation. |
| Q41825773 | Targeting the tumor-promoting microenvironment in MET-amplified NSCLC cells with a novel inhibitor of pro-HGF activation. |
| Q34141913 | The Hepatocyte Growth Factor Receptor: Structure, Function and Pharmacological Targeting in Cancer |
| Q41954928 | The MET Oncogene as a Therapeutical Target in Cancer Invasive Growth |
| Q24609682 | The MET axis as a therapeutic target |
| Q26752473 | The Role of miRNAs in the Regulation of Pancreatic Cancer Stem Cells |
| Q24314397 | The Slit/Robo system suppresses hepatocyte growth factor-dependent invasion and morphogenesis |
| Q33755200 | The angiotensin IV analog Nle-Tyr-Leu-psi-(CH2-NH2)3-4-His-Pro-Phe (norleual) can act as a hepatocyte growth factor/c-Met inhibitor |
| Q37621003 | The function, proteolytic processing, and histopathology of Met in cancer |
| Q35563524 | The hepatocyte growth factor/c-Met signaling pathway as a therapeutic target to inhibit angiogenesis |
| Q39594896 | The orally bioavailable met inhibitor PF-2341066 inhibits osteosarcoma growth and osteolysis/matrix production in a xenograft model |
| Q48381437 | The role of fatty acid β-oxidation in lymphangiogenesis |
| Q34386024 | The tetraspanin CD151 is required for Met-dependent signaling and tumor cell growth |
| Q36640026 | The tumor suppressor semaphorin 3B triggers a prometastatic program mediated by interleukin 8 and the tumor microenvironment |
| Q42698235 | Translational advances and novel therapies for pancreatic ductal adenocarcinoma: hope or hype? |
| Q36994041 | Turning the gene tap off; implications of regulating gene expression for cancer therapeutics |
| Q37948053 | Understanding tumor-stroma interplays for targeted therapies by armed mesenchymal stromal progenitors: the Mesenkillers |
| Q35112894 | VEGF and c-Met Blockade Amplify Angiogenesis Inhibition in Pancreatic Islet Cancer |
| Q37962905 | c-MET as a potential therapeutic target and biomarker in cancer |
| Q35199181 | c-Met gene amplification is associated with advanced stage colorectal cancer and liver metastases |
| Q42426376 | c-Met in pancreatic cancer stem cells: therapeutic implications. |
| Q27649203 | c-Met inhibitors with novel binding mode show activity against several hereditary papillary renal cell carcinoma-related mutations |
| Q37169357 | c-Met targeted therapy of cholangiocarcinoma |
Search more.